BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 23372043)

  • 1. A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in Huntington's disease.
    Hsiao HY; Chen YC; Chen HM; Tu PH; Chern Y
    Hum Mol Genet; 2013 May; 22(9):1826-42. PubMed ID: 23372043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expanded-polyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes.
    Chou SY; Weng JY; Lai HL; Liao F; Sun SH; Tu PH; Dickson DW; Chern Y
    J Neurosci; 2008 Mar; 28(13):3277-90. PubMed ID: 18367595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease.
    Hsiao HY; Chiu FL; Chen CM; Wu YR; Chen HM; Chen YC; Kuo HC; Chern Y
    Hum Mol Genet; 2014 Aug; 23(16):4328-44. PubMed ID: 24698979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system.
    Chiang MC; Chen HM; Lai HL; Chen HW; Chou SY; Chen CM; Tsai FJ; Chern Y
    Hum Mol Genet; 2009 Aug; 18(16):2929-42. PubMed ID: 19443488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington's disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation.
    Miguez A; García-Díaz Barriga G; Brito V; Straccia M; Giralt A; Ginés S; Canals JM; Alberch J
    Hum Mol Genet; 2015 Sep; 24(17):4958-70. PubMed ID: 26063761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.
    Ju TC; Chen HM; Chen YC; Chang CP; Chang C; Chern Y
    Biochim Biophys Acta; 2014 Sep; 1842(9):1668-80. PubMed ID: 24946181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cytokine and endocannabinoid systems are co-regulated by NF-κB p65/RelA in cell culture and transgenic mouse models of Huntington's disease and in striatal tissue from Huntington's disease patients.
    Laprairie RB; Warford JR; Hutchings S; Robertson GS; Kelly ME; Denovan-Wright EM
    J Neuroimmunol; 2014 Feb; 267(1-2):61-72. PubMed ID: 24360910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
    Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
    J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain.
    Lim NK; Hung LW; Pang TY; Mclean CA; Liddell JR; Hilton JB; Li QX; White AR; Hannan AJ; Crouch PJ
    Hum Mol Genet; 2014 Aug; 23(15):4051-63. PubMed ID: 24634145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
    Cho IK; Yang B; Forest C; Qian L; Chan AWS
    PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of Elk-1 participates as a neuroprotective compensatory mechanism in models of Huntington's disease.
    Anglada-Huguet M; Giralt A; Perez-Navarro E; Alberch J; Xifró X
    J Neurochem; 2012 May; 121(4):639-48. PubMed ID: 22372926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease.
    Swarnkar S; Chen Y; Pryor WM; Shahani N; Page DT; Subramaniam S
    Neurobiol Dis; 2015 Oct; 82():66-77. PubMed ID: 26048156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Astrocyte transduction is required for rescue of behavioral phenotypes in the YAC128 mouse model with AAV-RNAi mediated HTT lowering therapeutics.
    Stanek LM; Bu J; Shihabuddin LS
    Neurobiol Dis; 2019 Sep; 129():29-37. PubMed ID: 31042572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Degeneration of ipRGCs in Mouse Models of Huntington's Disease Disrupts Non-Image-Forming Behaviors Before Motor Impairment.
    Lin MS; Liao PY; Chen HM; Chang CP; Chen SK; Chern Y
    J Neurosci; 2019 Feb; 39(8):1505-1524. PubMed ID: 30587542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant astrocytes impair vascular reactivity in Huntington disease.
    Hsiao HY; Chen YC; Huang CH; Chen CC; Hsu YH; Chen HM; Chiu FL; Kuo HC; Chang C; Chern Y
    Ann Neurol; 2015 Aug; 78(2):178-92. PubMed ID: 25914140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of nuclear mutant huntingtin inclusion formation in neurons and glia is cell-type-specific.
    Jansen AH; van Hal M; Op den Kelder IC; Meier RT; de Ruiter AA; Schut MH; Smith DL; Grit C; Brouwer N; Kamphuis W; Boddeke HW; den Dunnen WF; van Roon WM; Bates GP; Hol EM; Reits EA
    Glia; 2017 Jan; 65(1):50-61. PubMed ID: 27615381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of brain-type creatine kinase activity ameliorates neuronal deficits in Huntington's disease.
    Lin YS; Cheng TH; Chang CP; Chen HM; Chern Y
    Biochim Biophys Acta; 2013 Jun; 1832(6):742-53. PubMed ID: 23416527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Astrocytes are key but indirect contributors to the development of the symptomatology and pathophysiology of Huntington's disease.
    Meunier C; Merienne N; Jollé C; Déglon N; Pellerin L
    Glia; 2016 Nov; 64(11):1841-56. PubMed ID: 27442486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of huntingtin pathologic fragments in human Huntington disease, transgenic mice, and cell models.
    Schilling G; Klevytska A; Tebbenkamp AT; Juenemann K; Cooper J; Gonzales V; Slunt H; Poirer M; Ross CA; Borchelt DR
    J Neuropathol Exp Neurol; 2007 Apr; 66(4):313-20. PubMed ID: 17413322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects.
    Faideau M; Kim J; Cormier K; Gilmore R; Welch M; Auregan G; Dufour N; Guillermier M; Brouillet E; Hantraye P; Déglon N; Ferrante RJ; Bonvento G
    Hum Mol Genet; 2010 Aug; 19(15):3053-67. PubMed ID: 20494921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.